drugset
drugset / Trial / NCT03618030

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03618030 ↗

Phase 3 Completed 288 enrolled Purdue Pharma, Canada
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults

Timeline

Start
2018-08-21
Primary completion
2019-07-05
Completion
2019-07-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 25 mg Oral
Subject Methylphenidate Small molecule 35 mg Oral
Subject Methylphenidate Small molecule 45 mg Oral
Subject Methylphenidate Small molecule 55 mg Oral
Subject Methylphenidate Small molecule 70 mg Oral
Subject Methylphenidate Small molecule 85 mg Oral
Subject Methylphenidate Small molecule 100 mg Oral

Indications

attention deficit-hyperactivity disorder